O	0	2	IL	IL	NN	B-NP
O	2	3	-	-	HYPH	I-NP
O	3	5	12	12	CD	I-NP
O	6	16	inhibition	inhibition	NN	I-NP
O	17	19	of	of	IN	B-PP
B-Cell	20	31	endothelial	endothelial	JJ	B-NP
I-Cell	32	36	cell	cell	NN	I-NP
O	37	46	functions	function	NNS	I-NP
O	47	50	and	and	CC	O
O	51	63	angiogenesis	angiogenesis	NN	B-NP
O	64	71	depends	depend	VBZ	B-VP
O	72	74	on	on	IN	B-PP
B-Cell	75	85	lymphocyte	lymphocyte	NN	B-NP
O	85	86	-	-	HYPH	B-NP
B-Cell	86	97	endothelial	endothelial	JJ	I-NP
I-Cell	98	102	cell	cell	NN	I-NP
O	103	108	cross	cross	AFX	B-NP
O	108	109	-	-	HYPH	I-NP
O	109	113	talk	talk	NN	B-NP
O	113	114	.	.	.	O

O	115	117	In	In	FW	B-NP
O	118	122	vivo	vivo	FW	I-NP
O	123	125	IL	IL	NN	I-NP
O	125	126	-	-	HYPH	B-NP
O	126	128	12	12	CD	I-NP
O	128	129	-	-	HYPH	I-NP
O	129	138	dependent	dependent	JJ	I-NP
B-Cancer	139	144	tumor	tumor	NN	I-NP
O	145	155	inhibition	inhibition	NN	I-NP
O	156	161	rests	rest	VBZ	B-VP
O	162	164	on	on	IN	B-PP
O	165	168	the	the	DT	B-NP
O	169	176	ability	ability	NN	I-NP
O	177	179	of	of	IN	B-PP
O	180	182	IL	IL	NN	B-NP
O	182	183	-	-	HYPH	B-NP
O	183	185	12	12	CD	I-NP
O	186	188	to	to	TO	B-VP
O	189	197	activate	activate	VB	I-VP
O	198	199	a	a	DT	B-NP
O	200	203	CD8	CD8	NN	I-NP
O	203	204	-	-	HYPH	O
O	204	212	mediated	mediate	VBN	B-NP
O	213	225	cytotoxicity	cytotoxicity	NN	I-NP
O	225	226	,	,	,	O
O	227	234	inhibit	inhibit	VBP	B-VP
O	235	247	angiogenesis	angiogenesis	NN	B-NP
O	247	248	,	,	,	O
O	249	252	and	and	CC	O
O	253	258	cause	cause	VBP	B-VP
B-Multi-tissue_structure	259	267	vascular	vascular	JJ	B-NP
O	268	274	injury	injury	NN	I-NP
O	274	275	.	.	.	O

O	276	284	Although	Although	IN	B-SBAR
O	285	287	in	in	FW	B-NP
O	288	292	vivo	vivo	FW	I-NP
O	293	300	studies	study	NNS	I-NP
O	301	305	have	have	VBP	B-VP
O	306	311	shown	show	VBN	I-VP
O	312	316	that	that	IN	B-SBAR
O	317	321	such	such	JJ	B-NP
O	322	332	inhibition	inhibition	NN	I-NP
O	333	338	stems	stem	VBZ	B-VP
O	339	343	from	from	IN	B-PP
O	344	351	complex	complex	JJ	B-NP
O	352	364	interactions	interaction	NNS	I-NP
O	365	367	of	of	IN	B-PP
B-Cell	368	374	immune	immune	JJ	B-NP
I-Cell	375	380	cells	cell	NNS	I-NP
O	381	384	and	and	CC	O
O	385	388	the	the	DT	B-NP
O	389	399	production	production	NN	I-NP
O	400	402	of	of	IN	B-PP
O	403	406	IFN	IFN	NN	B-NP
O	406	407	-	-	HYPH	O
O	407	412	gamma	gamma	SYM	B-NP
O	413	416	and	and	CC	O
O	417	422	other	other	JJ	B-NP
O	423	433	downstream	downstream	JJ	I-NP
O	434	445	angiostatic	angiostatic	JJ	I-NP
O	446	456	chemokines	chemokine	NNS	I-NP
O	456	457	,	,	,	O
O	458	461	the	the	DT	B-NP
O	462	472	mechanisms	mechanism	NNS	I-NP
O	473	481	involved	involve	VBN	B-VP
O	482	485	are	be	VBP	B-VP
O	486	491	still	still	RB	B-ADVP
O	492	498	poorly	poorly	RB	B-ADJP
O	499	506	defined	define	VBN	I-ADJP
O	506	507	.	.	.	O

O	508	512	Here	Here	RB	B-ADVP
O	513	515	we	we	PRP	B-NP
O	516	520	show	show	VBP	B-VP
O	521	525	that	that	IN	B-SBAR
O	526	528	IL	IL	NN	B-NP
O	528	529	-	-	HYPH	B-NP
O	529	531	12	12	CD	I-NP
O	532	541	activates	activate	VBZ	B-VP
O	542	544	an	an	DT	B-NP
O	545	549	anti	anti	AFX	I-NP
O	549	550	-	-	HYPH	I-NP
O	550	560	angiogenic	angiogenic	JJ	I-NP
O	561	568	program	program	NN	I-NP
O	569	571	in	in	IN	B-PP
O	572	575	Con	Con	NN	B-NP
O	576	577	A	A	NN	I-NP
O	577	578	-	-	HYPH	B-NP
O	578	587	activated	activate	VBN	I-NP
O	588	593	mouse	mouse	NN	I-NP
B-Cell	594	600	spleen	spleen	NN	I-NP
I-Cell	601	606	cells	cell	NNS	I-NP
O	607	608	(	(	(	O
O	608	617	activated	activate	VBN	B-NP
B-Cell	618	621	spc	spc	NN	I-NP
O	621	622	)	)	)	O
O	623	625	or	or	CC	O
O	626	631	human	human	JJ	B-NP
B-Cell	632	636	PBMC	PBMC	NN	I-NP
O	637	638	(	(	(	O
O	638	647	activated	activate	VBN	B-NP
B-Cell	648	652	PBMC	PBMC	NN	I-NP
O	652	653	)	)	)	O
O	653	654	.	.	.	O

O	655	658	The	The	DT	B-NP
O	659	666	soluble	soluble	JJ	I-NP
O	667	674	factors	factor	NNS	I-NP
O	675	679	they	they	PRP	B-NP
O	680	687	release	release	VBP	B-VP
O	688	690	in	in	IN	B-PP
O	691	694	its	its	PRP$	B-NP
O	695	703	presence	presence	NN	I-NP
O	704	710	arrest	arrest	NN	I-NP
O	711	714	the	the	DT	B-NP
O	715	720	cycle	cycle	NN	I-NP
O	721	723	of	of	IN	B-PP
B-Cell	724	735	endothelial	endothelial	JJ	B-NP
I-Cell	736	741	cells	cell	NNS	I-NP
O	742	743	(	(	(	O
B-Cell	743	745	EC	EC	NN	B-NP
O	745	746	)	)	)	O
O	746	747	,	,	,	O
O	748	755	inhibit	inhibit	VBP	B-VP
O	756	758	in	in	FW	B-NP
O	759	764	vitro	vitro	FW	I-NP
O	765	777	angiogenesis	angiogenesis	NN	I-NP
O	777	778	,	,	,	O
O	779	789	negatively	negatively	RB	B-ADVP
O	790	798	modulate	modulate	VBP	B-VP
O	799	802	the	the	DT	B-NP
O	803	813	production	production	NN	I-NP
O	814	816	of	of	IN	B-PP
O	817	823	matrix	matrix	NN	B-NP
O	824	841	metalloproteinase	metalloproteinase	NN	I-NP
O	841	842	-	-	HYPH	B-NP
O	842	843	9	9	CD	I-NP
O	843	844	,	,	,	O
O	845	848	and	and	CC	O
O	849	852	the	the	DT	B-NP
O	853	860	ability	ability	NN	I-NP
O	861	863	of	of	IN	B-PP
B-Cell	864	866	EC	EC	NN	B-NP
O	867	869	to	to	TO	B-VP
O	870	876	adhere	adhere	VB	I-VP
O	877	879	to	to	TO	B-PP
O	880	891	vitronectin	vitronectin	NN	B-NP
O	892	895	and	and	CC	O
O	896	898	up	up	RB	B-VP
O	898	899	-	-	HYPH	I-VP
O	899	907	regulate	regulate	VB	I-VP
O	908	912	ICAM	ICAM	NN	B-NP
O	912	913	-	-	HYPH	B-NP
O	913	914	1	1	CD	I-NP
O	915	918	and	and	CC	I-NP
O	919	923	VCAM	VCAM	NN	I-NP
O	923	924	-	-	HYPH	O
O	924	925	1	1	CD	B-NP
O	926	936	expression	expression	NN	I-NP
O	936	937	.	.	.	O

O	938	943	These	These	DT	B-NP
O	944	951	effects	effect	NNS	I-NP
O	952	954	do	do	VBP	B-VP
O	955	958	not	not	RB	I-VP
O	959	966	require	require	VB	I-VP
O	967	973	direct	direct	JJ	B-NP
B-Cellular_component	974	978	cell	cell	NN	I-NP
I-Cellular_component	978	979	-	-	HYPH	B-NP
I-Cellular_component	979	983	cell	cell	NN	I-NP
I-Cellular_component	984	991	contact	contact	NN	I-NP
O	991	992	,	,	,	O
O	993	996	yet	yet	RB	B-ADVP
O	997	1003	result	result	VBP	B-VP
O	1004	1008	from	from	IN	B-PP
O	1009	1019	continuous	continuous	JJ	B-NP
O	1020	1031	interaction	interaction	NN	I-NP
O	1032	1039	between	between	IN	B-PP
O	1040	1049	activated	activate	VBN	B-NP
B-Cell	1050	1058	lymphoid	lymphoid	JJ	I-NP
I-Cell	1059	1064	cells	cell	NNS	I-NP
O	1065	1068	and	and	CC	O
B-Cell	1069	1071	EC	EC	NN	B-NP
O	1071	1072	.	.	.	O

O	1073	1075	We	We	PRP	B-NP
O	1076	1080	used	use	VBD	B-VP
O	1081	1093	neutralizing	neutralize	VBG	B-VP
O	1094	1097	Abs	Ab	NNS	B-NP
O	1098	1100	to	to	TO	B-VP
O	1101	1105	show	show	VB	I-VP
O	1106	1110	that	that	IN	B-SBAR
O	1111	1114	the	the	DT	B-NP
O	1115	1118	IFN	IFN	NN	I-NP
O	1118	1119	-	-	HYPH	O
O	1119	1128	inducible	inducible	JJ	B-NP
O	1129	1136	protein	protein	NN	I-NP
O	1136	1137	-	-	HYPH	B-NP
O	1137	1139	10	10	CD	I-NP
O	1140	1143	and	and	CC	I-NP
O	1144	1152	monokine	monokine	NN	I-NP
O	1152	1153	-	-	HYPH	B-NP
O	1153	1160	induced	induce	VBN	B-VP
O	1161	1163	by	by	IN	B-PP
O	1164	1167	IFN	IFN	NN	B-NP
O	1167	1168	-	-	HYPH	O
O	1168	1173	gamma	gamma	SYM	O
O	1174	1184	chemokines	chemokine	NNS	B-NP
O	1185	1188	are	be	VBP	B-VP
O	1189	1196	pivotal	pivotal	JJ	B-ADJP
O	1197	1199	in	in	IN	B-PP
O	1200	1208	inducing	induce	VBG	B-VP
O	1209	1214	these	these	DT	B-NP
O	1215	1222	effects	effect	NNS	I-NP
O	1222	1223	.	.	.	O

O	1224	1235	Experiments	Experiment	NNS	B-NP
O	1236	1240	with	with	IN	B-PP
O	1241	1243	nu	nu	NN	B-NP
O	1243	1244	/	/	SYM	B-NP
O	1244	1246	nu	nu	NN	I-NP
O	1247	1251	mice	mouse	NNS	I-NP
O	1251	1252	,	,	,	O
O	1253	1261	nonobese	nonobese	JJ	B-NP
O	1262	1270	diabetic	diabetic	JJ	I-NP
O	1270	1271	-	-	HYPH	I-NP
O	1271	1275	SCID	SCID	NN	I-NP
O	1276	1280	mice	mouse	NNS	I-NP
O	1280	1281	,	,	,	O
O	1282	1284	or	or	CC	O
O	1285	1294	activated	activate	VBN	B-NP
B-Cell	1295	1298	spc	spc	NN	I-NP
O	1299	1307	enriched	enrich	VBN	B-VP
O	1308	1310	in	in	IN	B-PP
O	1311	1319	specific	specific	JJ	B-NP
B-Cell	1320	1324	cell	cell	NN	I-NP
O	1325	1339	subpopulations	subpopulation	NNS	I-NP
O	1340	1352	demonstrated	demonstrate	VBD	B-VP
O	1353	1357	that	that	IN	B-SBAR
B-Cell	1358	1361	CD4	CD4	NN	B-NP
I-Cell	1361	1362	(	(	(	O
I-Cell	1362	1363	+	+	SYM	B-NP
I-Cell	1363	1364	)	)	)	O
O	1364	1365	,	,	,	O
B-Cell	1366	1369	CD8	CD8	NN	B-NP
I-Cell	1369	1370	(	(	(	O
I-Cell	1370	1371	+	+	SYM	B-NP
I-Cell	1371	1372	)	)	)	O
O	1372	1373	,	,	,	O
O	1374	1377	and	and	CC	O
B-Cell	1378	1380	NK	NK	NN	B-NP
I-Cell	1381	1386	cells	cell	NNS	I-NP
O	1387	1390	are	be	VBP	B-VP
O	1391	1394	all	all	DT	O
O	1395	1401	needed	need	VBN	B-VP
O	1402	1404	to	to	TO	B-VP
O	1405	1412	mediate	mediate	VB	I-VP
O	1413	1416	the	the	DT	B-NP
O	1417	1421	full	full	JJ	I-NP
O	1422	1426	anti	anti	AFX	I-NP
O	1426	1427	-	-	HYPH	I-NP
O	1427	1439	angiogenetic	angiogenetic	JJ	I-NP
O	1440	1446	effect	effect	NN	I-NP
O	1447	1449	of	of	IN	B-PP
O	1450	1452	IL	IL	NN	B-NP
O	1452	1453	-	-	HYPH	B-NP
O	1453	1455	12	12	CD	I-NP
O	1455	1456	.	.	.	O

